TF and prostate carcinoma: Taken together, our data indicate a novel, crucial role for AR in reducing TF expression, which could be important for increased TF expression and TF‐positive MV release in androgen‐deprived prostate cancer patients, and contribute to elevated VTE rates in prostate cancer patients.